CHONGQING, CHINA - FEBRUARY 3: In this photo illustration, a smartphone displays the logo of Moderna, Inc. (NASDAQ: MRNA), a U.S.-based biotechnology company specializing in messenger RNA (mRNA) ...
Investors in Moderna Inc (Symbol: MRNA) saw new options become available today, for the January 2026 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MRNA ...
Moderna (MRNA) stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return. The company’s value has increased by approximately $1.2 billion over ...
Investors in Moderna Inc (Symbol: MRNA) saw new options begin trading today, for the December 26th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MRNA options ...
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer ...
In high-risk melanoma patients who had undergone complete tumor removal, adding Moderna's mRNA-4157 to Keytruda reduced the risk of recurrence or death by 49% versus Keytruda alone. The combination ...
Moderna (MRNA) reported better-than-expected Q4 2025 financials on Friday and reaffirmed its 2026 growth target even as the vaccine maker suffered a major regulatory setback for its flu shot candidate ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Moderna (MRNA) stock has shed roughly 90% of its value since its 2021 peak.
Moderna (NasdaqGS:MRNA) has reached a global settlement with Genevant Sciences and Arbutus Biopharma over lipid nanoparticle technology used in its Covid 19 vaccines. The agreement includes a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results